1-4 of 4
Jacques Bonneterre
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data

Free
Jean-Yves Pierga, Thierry Petit, Christelle Lévy, Jean-Marc Ferrero, Mario Campone, Joseph Gligorov, Florence Lerebours, Henri Roché, Thomas Bachelot, Emmanuelle Charafe-Jauffret, Jacques Bonneterre, Juana Hernandez, François-Clément Bidard, Patrice Viens
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (6): 1298–1304.
https://doi.org/10.1158/1078-0432.CCR-14-1705
Published: 12 March 2015
View articletitled, Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data
Open the PDF for Pathological Response and Circulating Tumor Cell Count Identifies Treated HER2+ Inflammatory Breast Cancer Patients with Excellent Prognosis: BEVERLY-2 Survival Data in another window
Journal Articles

Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors

Free
Isa E.L.M. Kuppens, Eric Dansin, Henk Boot, Celine Feger, Sylvia Assadourian, Maria-Edith Bonneterre, Jos H. Beijnen, Jan H.M. Schellens, Jacques Bonneterre
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (12): 3774–3781.
https://doi.org/10.1158/1078-0432.CCR-05-2368
Published: 15 June 2006
View articletitled, Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors
Open the PDF for Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies

Free
Véronique Diéras, Jacques Bonneterre, Valérie Laurence, Marian Degardin, Jean-Yves Pierga, Marie-Edith Bonneterre, Sandrine Marreaud, Denis Lacombe, Pierre Fumoleau
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (17): 6256–6260.
https://doi.org/10.1158/1078-0432.CCR-04-2316
Published: 06 September 2005
View articletitled, Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies
Open the PDF for Phase I Combining a P-Glycoprotein Inhibitor, MS209, in Combination with Docetaxel in Patients with Advanced Malignancies in another window
Journal Articles

Prognostic Value of Circulating Soluble E-Selectin Concentrations in Node-negative Breast Cancer Patients

Free
Mohamed Hebbar, Françcoise Révillion, Marie-Michèle Louchez, Charles Fournier, Jacques Bonneterre, Jean-Philippe Peyrat
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (6): 1427–1433.
Published: 01 June 1999
View articletitled, Prognostic Value of Circulating Soluble E-Selectin Concentrations in Node-negative Breast Cancer Patients
Open the PDF for Prognostic Value of Circulating Soluble E-Selectin Concentrations in Node-negative Breast Cancer Patients in another window